Lee's Pharmaceutical Holdings Limited stock analysis
Want to see HK:0950 full AI Analyst Report?
TTM revenue growth of approximately 30% indicates strong recent demand and expanding commercial activity across the company’s pharmaceutical portfolio. Sustained top-line momentum can support greater operating scale, product investment, regulatory activities, and broader market penetration over the next several quarters.
A gross margin in the low-to-mid 50% range suggests the company’s products retain meaningful economic value after production costs. The improvement in net margin to about 8.6% also shows better earnings conversion, creating more capacity to support commercialization and research activities.
Low leverage and a sizable equity base provide financial flexibility for an integrated pharmaceutical business operating across research, registration, production, and sales. The conservative capital structure reduces refinancing pressure and improves resilience while allowing resources to remain available for growth initiatives.
Weak TTM EBIT compared with prior annual periods raises concern about the durability of operating earnings despite strong revenue growth. Profit volatility makes future performance harder to underwrite and suggests that product mix, operating costs, or commercialization economics may not yet be consistently favorable.
The swing from negative to positive free cash flow indicates that cash generation has not been consistently dependable across periods. TTM free cash flow at roughly 72% of net income also points to variability from working-capital and capital-spending demands, which can constrain internally funded investment.
Although TTM ROE has improved, its historically uneven level indicates that the company has not consistently converted its capital base into strong shareholder returns. This may limit confidence in the repeatability of earnings performance and suggests that balance-sheet strength has not always translated into efficient profitability.
Lee’s Pharmaceutical Holdings Limited ( ($HK:0950) ) has issued an announcement. Lee’s Pharmaceutical has strengthened its oncology portfolio by securing exclusive rights from U.S. biotech 1cBio to develop, manufacture and
Lee’s Pharmaceutical Holdings Limited ( ($HK:0950) ) has issued an update. Lee’s Pharmaceutical Holdings Limited expects to report an unaudited net profit attributable to shareholders of HK$85 million to HK$95
Lee’s Pharmaceutical Holdings Limited ( ($HK:0950) ) has shared an update. Lee’s Pharmaceutical Holdings Limited has signed an exclusive license-out and supply agreement with Ashlins Ocular Pharmaceuticals, a U.S.-based biopharmaceutical
The latest announcement is out from Lee’s Pharmaceutical Holdings Limited ( ($HK:0950) ). Lee’s Pharmaceutical Holdings Limited is a China-based biopharmaceutical company with over three decades of industry experience, operating
Lee’s Pharmaceutical Holdings Limited ( ($HK:0950) ) has shared an update. Shareholders of Lee’s Pharmaceutical Holdings Limited approved all 10 resolutions at the company’s annual general meeting held on 21
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 7 |
| Technical Analysis | 3 | 5 | 1 |
| Moving Averages | 6 | 0 | 6 |
